Condition

HCC - Hepatocellular Carcinoma clinical trials and research

• 41Clinical trials
• 1New in 30 days
• 11Countries

Newest HCC - Hepatocellular Carcinoma clinical trials

All recruiting trials (41)

• TACE plus SBRT before liver transplant for hepatocellular carcinoma

  This study tests whether adding SBRT to standard TACE helps liver transplant patients with hepatocellular carcinoma see better outcomes.

  Recruiting AIO-Studien-gGmbH · München · NCT07924943

• Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

  Doctors test whether a patient’s own 3D-bioprinted liver model can help choose the best additional treatment to lower the chance of cancer coming back after liver surgery.

  Recruiting The University of Hong Kong · Hong Kong · NCT07839767

• Real-world view of systemic therapies for advanced HCC at a single center

  This study looks at how patients with advanced hepatocellular carcinoma respond to systemic treatments in real-world practice at Mansoura University Hospitals.

  Recruiting Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07814014

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

• SIRT-Y90 with Atezolizumab and Bevacizumab for unresectable liver cancer

  This study looks at whether adding SIRT-Y90 to atezolizumab and bevacizumab can help adults with unresectable hepatocellular carcinoma see better responses and keep cancer from progressing.

  Recruiting Air Force Military Medical University, China · Xi’an, Shanxi · NCT07610551

• Ablative Dose Testing for Y-90 Radiation Segmentectomy in Liver Cancer

  This study tests the best Y-90 radiation dose to fully ablate liver tumors in adults who can’t be removed or treated with standard methods.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT07586046

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• Epalrestat with HAIC, Donafenib, and Tislelizumab as first-line therapy for unresectable HCC with diabetes

  This study tests a four-drug treatment combo to see if it can help adults with unresectable hepatocellular carcinoma and diabetes.

  Recruiting Phase 2 First Hospital of China Medical University · Harbin, Heilongjiang and 3 other locations · NCT07557914

• CVM-1118 plus sintilimab infusions and TACE for incurable non-metastatic liver cancer

  This trial will test whether combining oral CVM-1118 with sintilimab infusions and TACE helps people with incurable, non-metastatic hepatocellular carcinoma.

  Recruiting at 2 sites Phase 2 TaiRx, Inc. · Fuzhou, Fujian and 1 other locations · NCT07521852

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• Neoadjuvant tislelizumab plus lenvatinib for resectable hepatocellular carcinoma at high risk of recurrence

  This trial tests whether giving tislelizumab and lenvatinib before surgery can reduce recurrence and improve outcomes in people with resectable hepatocellular carcinoma at high risk of coming back.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07475026

• Surgery vs. Watch-and-Wait for patients with hepatocellular carcinoma who respond to conversion therapy

  This study tests whether surgical removal of liver tumors is better or worse than continuing with watchful waiting in people with HCC who have already responded to conversion therapy and are eligible for liver resection.

  Recruiting West China Hospital · Chengdu · NCT07410715

• TGI-5 alone and with nivolumab for advanced or metastatic solid tumors

  This trial tests whether TGI-5 by itself or combined with nivolumab is safe and can shrink tumors in adults with advanced or metastatic colorectal cancer, melanoma, hepatocellular carcinoma, or non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1 Hefei TG ImmunoPharma Co., Ltd. · Shanghai · NCT07376707

• Using spectral CT to check tumor response after TACE in hepatocellular carcinoma

  This study tests whether spectral CT can better detect tumor response after TACE in adults with early-to-intermediate hepatocellular carcinoma.

  Recruiting Zhongda Hospital · Nanjing · NCT07351669

• AST-3424 versus regorafenib for AKR1C3-high advanced liver cancer

  This trial tests whether AST-3424 can help people with AKR1C3-high advanced liver cancer who progressed after immune checkpoint inhibitor therapy, compared with regorafenib.

  Recruiting Phase 2 Zhejiang Hisun Pharmaceutical Co. Ltd. · Nanjing, Jiangsu · NCT07310173

• Combined immunotherapy and stereotactic radiotherapy to shrink unresectable liver cancer for possible surgery

  This project will test whether stereotactic body radiotherapy followed by immunotherapy can shrink unresectable hepatocellular carcinoma so surgery becomes possible for adults with preserved liver function.

  Recruiting The University of Hong Kong · Hong Kong · NCT07305428

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• Immunotherapy plus anti‑VEGF drugs with or without TACE/HAIC for advanced liver cancer

  This trial will try combining immune checkpoint drugs and anti‑VEGF medication, with or without interventional liver procedures, to treat adults with advanced hepatocellular carcinoma.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07157969

• Emotional stress and immunotherapy outcomes in liver cancer

  This study will see if emotional distress changes how well immunotherapy works for people with hepatocellular carcinoma.

  Recruiting at 5 sites Guilin Medical University, China · Zhanjiang, Guangdong and 4 other locations · NCT07141056

• Comparing blood thinners for people with cirrhosis and portal vein clots

  This will try enoxaparin, warfarin, or apixaban in people with cirrhosis and portal vein thrombosis (with or without liver cancer) to see which controls the clot and is safest.

  Recruiting Phase 4 Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07132515

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• GV20-0251 treatment for adults with advanced solid tumors

  This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.

  Recruiting at 3 sites Phase 1/2 GV20 Therapeutics · Beijing, Beijing Municipality and 2 other locations · NCT07070518

• Non-invasive tests to predict outcomes after curative treatment for hepatocellular carcinoma

  This project will test whether regular non-invasive liver and spleen stiffness checks plus scheduled endoscopies can help predict future complications in people with compensated chronic liver disease who receive curative-intent treatment for HCC.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT07036874

• Blood ctDNA monitoring for hepatocellular carcinoma and colorectal cancer that spread to the liver

  This trial tests whether a blood test that detects circulating tumor DNA (ctDNA) can track recurrence or progression in adults undergoing liver surgery or transplant for HCC or colorectal cancer with liver-only metastases.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07001085

• Multiparametric dynamic whole-body [68Ga]Ga-PSMA PET/CT for hepatocellular carcinoma

  This will test whether multiparametric dynamic whole-body [68Ga]Ga-PSMA PET/CT can better detect and characterize hepatocellular carcinoma in adults who are newly diagnosed or who have suspected recurrent, residual, or refractory disease.

  Recruiting Nantes University Hospital · Clichy and 1 other locations · NCT06999837

• Photon radiotherapy plus tremelimumab and durvalumab for intermediate or advanced hepatocellular carcinoma

  This trial tests whether adding targeted photon radiotherapy to tremelimumab plus durvalumab helps people with unresectable intermediate or advanced (BCLC B or C) hepatocellular carcinoma respond better to treatment.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999707

• Proton radiation with tremelimumab and durvalumab for BCLC stage B/C hepatocellular carcinoma

  This will test whether adding precise proton radiation to tremelimumab plus durvalumab helps people with unresectable BCLC stage B or C hepatocellular carcinoma.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999694

• Combination treatment for advanced liver cancer with FGF19 overexpression

  This study is testing a new combination treatment for advanced liver cancer to see if it can help patients whose cancer has not responded to other therapies.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT06978933

• Effects of radiotherapy on circulating tumor DNA in liver cancer patients

  This study is testing how Stereotactic Body Radiation Therapy affects levels of tumor DNA in the blood of liver cancer patients to see if it can help track how well the treatment is working.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT06885879

• Testing LXP1788 Injection for Advanced Solid Tumors

  This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 LaunXP Biomedical Co., Ltd. · Taichung and 1 other locations · NCT06883539

• Radiotherapy for patients with oligoprogressive liver cancer after PD-1 therapy

  This study is testing if adding radiation therapy can help people with liver cancer who have had some success with PD-1 therapy but are starting to see their cancer progress.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06870942

• Impact of muscle loss on treatment outcomes in liver cancer

  This study looks at how losing muscle affects treatment results and survival in people with liver cancer over a year after starting chemotherapy.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06805552

• Assessing elastography's role in predicting liver cancer recurrence after treatment

  This study is testing if a non-invasive method called elastography can help predict if liver cancer will come back after treatment in patients who have undergone radiofrequency ablation.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06777017

• Observing the effects of intra-arterial therapies for liver cancer

  This study is trying to find the best ways to help people with liver cancer get better results from a treatment called intra-arterial therapy.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06774690

• Needle-based treatment for liver tumors

  This study is testing a new needle treatment for liver tumors to see if it can completely destroy the tumors in adults who can't have surgery.

  Recruiting inTumo Therapeutics, Inc. · Topkapı, Istanbul · NCT06689670

• MTS105 treatment for advanced liver cancer

  This study is testing a new treatment called MTS105 for people with advanced liver cancer to see if it can help their immune system fight the cancer after other treatments haven't worked.

  Recruiting Phase 1 Peking University · Beijing · NCT06689540

• Fecal microbiota transfer to overcome resistance to atezolizumab/bevacizumab in liver cancer

  This will test whether adding fecal microbiota transfer to standard atezolizumab/bevacizumab helps adults with advanced hepatocellular carcinoma respond better.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 6 other locations · NCT05690048

• Observational cohort for non-alcoholic fatty liver disease and related conditions

  This study is trying to learn more about non-alcoholic fatty liver disease and its related conditions by looking at patients with different stages of the disease and comparing them to people with diabetes and obesity who don't have it.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Rome/lazio/italy · NCT04371042

Related topics

Quick answers

How many HCC - Hepatocellular Carcinoma clinical trials are recruiting right now?

41, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in China (21 trials), Italy (4 trials), Hong Kong (4 trials), Taiwan (3 trials), Germany (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 4, Phase 2/3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →